AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Sana Biotechnology, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Sana Biotechnology (NASDAQ: SANA) filed an 8-K disclosing key Q2-Q3 developments. The company estimates it held $90.1 million in cash, cash equivalents and marketable securities on 31 Jul 2025. Between 1 Apr and 6 Aug 2025 it raised $29.1 million of net proceeds through the sale of 7,441,376 common shares under its at-the-market program.

Sana will record a $40-45 million non-cash impairment in May 2025 linked to suspended build-out and planned subleases of its Bothell and Seattle facilities. Operationally, June 2025 six-month data from the investigator-sponsored UP421 trial met all primary and secondary endpoints, demonstrating insulin-producing β-cell function without immunosuppression; results were later published in NEJM. Pre-clinical candidate SC451 advanced following a favorable FDA INTERACT meeting. Conversely, Senior VP & Head of the Hypoimmune Platform Dr. Sonja Schrepfer resigned. All financial figures are unaudited and subject to change.

Sana Biotechnology (NASDAQ: SANA) ha presentato un modulo 8-K divulgando i principali sviluppi del secondo e terzo trimestre. L'azienda stima di aver detenuto 90,1 milioni di dollari in contanti, equivalenti di cassa e titoli negoziabili al 31 luglio 2025. Tra il 1° aprile e il 6 agosto 2025 ha raccolto 29,1 milioni di dollari di proventi netti attraverso la vendita di 7.441.376 azioni ordinarie nell'ambito del suo programma di vendita sul mercato.

Sana registrerà una perdita non monetaria di valore compresa tra 40 e 45 milioni di dollari a maggio 2025, legata alla sospensione della costruzione e ai subaffitti pianificati delle sue strutture di Bothell e Seattle. Dal punto di vista operativo, i dati a sei mesi di giugno 2025 dello studio UP421, promosso da un investigatore, hanno soddisfatto tutti gli endpoint primari e secondari, dimostrando la funzione delle cellule β produttrici di insulina senza immunosoppressione; i risultati sono stati successivamente pubblicati su NEJM. Il candidato pre-clinico SC451 ha fatto progressi dopo un incontro positivo con la FDA INTERACT. Al contrario, la Vicepresidente Senior e Responsabile della Piattaforma Hypoimmune, la dott.ssa Sonja Schrepfer, si è dimessa. Tutte le cifre finanziarie sono non revisionate e soggette a modifiche.

Sana Biotechnology (NASDAQ: SANA) presentó un formulario 8-K divulgando desarrollos clave del segundo y tercer trimestre. La compañía estima que tenía 90,1 millones de dólares en efectivo, equivalentes de efectivo y valores negociables al 31 de julio de 2025. Entre el 1 de abril y el 6 de agosto de 2025, recaudó 29,1 millones de dólares netos mediante la venta de 7.441.376 acciones comunes bajo su programa de colocación en el mercado.

Sana registrará una pérdida por deterioro no monetaria de 40 a 45 millones de dólares en mayo de 2025, vinculada a la suspensión de la construcción y los subarrendamientos planificados de sus instalaciones en Bothell y Seattle. Operativamente, los datos a seis meses de junio de 2025 del ensayo patrocinado por investigadores UP421 cumplieron con todos los objetivos primarios y secundarios, demostrando la función de células β productoras de insulina sin inmunosupresión; los resultados fueron publicados posteriormente en NEJM. El candidato preclínico SC451 avanzó tras una reunión favorable con la FDA INTERACT. Por otro lado, la Vicepresidenta Senior y Jefa de la Plataforma Hypoimmune, la Dra. Sonja Schrepfer renunció. Todas las cifras financieras son no auditadas y están sujetas a cambios.

Sana Biotechnology (NASDAQ: SANA)ëŠ� 2분기와 3분기 주요 ì§„í–‰ ìƒí™©ì� 공개하는 8-K 보고서를 제출했습니다. 회사ëŠ� 2025ë…� 7ì›� 31ì� 기준 현금, 현금ì„� ìžì‚° ë°� 시장ì„� ì¦ê¶Œìœ¼ë¡œ 9,010ë§� 달러ë¥� 보유í•� 것으ë¡� 추정합니ë‹�. 2025ë…� 4ì›� 1ì¼ë¶€í„� 8ì›� 6ì¼ê¹Œì§€ 시장 ë‚� 프로그램ì� 통해 7,441,376ì£¼ì˜ ë³´í†µì£¼ë¥¼ íŒë§¤í•˜ì—¬ 2,910ë§� 달러ì� 순수ìµì„ 조달했습니다.

SanaëŠ� 2025ë…� 5ì›”ì— ë³´í…” ë°� 시애틀 시설ì� 건설 중단 ë°� 계íšë� 서브리스와 관련하ì—� 4,000ë§Œ~4,500ë§� 달러ì� 비현ê¸� ì†ìƒì°¨ì†ì� 기ë¡í•� 예정입니ë‹�. ìš´ì˜ ì¸¡ë©´ì—서, 2025ë…� 6ì›”ì— ì¡°ì‚¬ìž� ì£¼ë„ UP421 ìž„ìƒì‹œí—˜ì� 6개월 ë°ì´í„°ëŠ” 모든 1ì°� ë°� 2ì°� í‰ê°€ë³€ìˆ˜ë¥¼ 충족했으ë©�, 면역억제 ì—†ì´ ì¸ìŠë¦� ìƒì‚° ë² íƒ€ì„¸í¬ ê¸°ëŠ¥ì� ìž…ì¦í–ˆìŠµë‹ˆë‹¤; ê²°ê³¼ëŠ� ì´í›„ NEJMì—� 게재ë˜ì—ˆìŠµë‹ˆë‹�. ì „ìž„ìƒ� 후보물질 SC451ì€ FDA INTERACT 회ì˜ì—서 ê¸ì •ì ì¸ í‰ê°€ë¥� 받아 ì§„ì „ì� 보였습니ë‹�. 반면, Hypoimmune 플랫í¼ì˜ ìˆ˜ì„ ë¶€ì‚¬ìž¥ ê²� ì±…ìž„ìžì¸ ì†ì•¼ 슈레í� ë°•ì‚¬ë‹˜ì´ ì‚¬ìž„í–ˆìŠµë‹ˆë‹¤. 모든 재무 수치ëŠ� ê°ì‚¬ë˜ì§€ 않았으며 ë³€ê²½ë  ìˆ� 있습니다.

Sana Biotechnology (NASDAQ : SANA) a déposé un formulaire 8-K révélant les principaux développements des deuxième et troisième trimestres. La société estime détenir 90,1 millions de dollars en liquidités, équivalents de liquidités et titres négociables au 31 juillet 2025. Entre le 1er avril et le 6 août 2025, elle a levé 29,1 millions de dollars de produits nets grâce à la vente de 7 441 376 actions ordinaires dans le cadre de son programme de placement en continu.

Sana enregistrera une dépréciation non monétaire de 40 à 45 millions de dollars en mai 2025, liée à la suspension de la construction et aux sous-locations prévues de ses installations de Bothell et Seattle. Sur le plan opérationnel, les données à six mois de juin 2025 de l'essai UP421, sponsorisé par un investigateur, ont atteint tous les critères principaux et secondaires, démontrant la fonction des cellules β productrices d'insuline sans immunosuppression ; les résultats ont ensuite été publiés dans le NEJM. Le candidat préclinique SC451 a progressé suite à une réunion favorable avec la FDA INTERACT. En revanche, la vice-présidente senior et responsable de la plateforme Hypoimmune, Dr Sonja Schrepfer, a démissionné. Toutes les données financières sont non auditées et susceptibles d’être modifiées.

Sana Biotechnology (NASDAQ: SANA) reichte ein 8-K ein, in dem wichtige Entwicklungen im zweiten und dritten Quartal offengelegt wurden. Das Unternehmen schätzt, dass es am 31. Juli 2025 über 90,1 Millionen US-Dollar an Bargeld, Zahlungsmitteln und marktfähigen Wertpapieren verfügte. Zwischen dem 1. April und dem 6. August 2025 erzielte es 29,1 Millionen US-Dollar Nettoproven durch den Verkauf von 7.441.376 Stammaktien im Rahmen seines At-the-Market-Programms.

Sana wird im Mai 2025 eine nicht zahlungswirksame Wertminderung in Höhe von 40 bis 45 Millionen US-Dollar verbuchen, die mit der Aussetzung des Ausbaus und den geplanten Untermietungen seiner Einrichtungen in Bothell und Seattle zusammenhängt. Operativ erfüllten die sechsmonatigen Daten der im Juni 2025 vom Prüfer initiierten UP421-Studie alle primären und sekundären Endpunkte und zeigten eine Insulin-produzierende β-Zellfunktion ohne Immunsuppression; die Ergebnisse wurden später im NEJM veröffentlicht. Der präklinische Kandidat SC451 machte Fortschritte nach einem positiven FDA-INTERACT-Treffen. Im Gegensatz dazu trat Dr. Sonja Schrepfer, Senior Vice President und Leiterin der Hypoimmune-Plattform, zurück. Alle finanziellen Zahlen sind unauditiert und können sich ändern.

Positive
  • UP421 six-month trial met all endpoints, with data published in NEJM, supporting Sana’s hypoimmune platform.
  • FDA INTERACT meeting advanced pre-clinical candidate SC451 toward GMP manufacturing.
  • $29.1 million ATM proceeds raised, boosting liquidity to an estimated $90.1 million.
  • Shift to third-party manufacturing may lower future capital expenditures.
Negative
  • $40-45 million non-cash impairment on Bothell and Seattle facilities.
  • Suspension of internal manufacturing build-out signals revised capacity strategy.
  • Resignation of SVP & Head of Hypoimmune Platform Dr. Sonja Schrepfer introduces leadership risk.

Insights

TL;DR: Positive clinical read-out offsets one-time impairment; liquidity modest but bolstered by ATM.

The UP421 six-month data, published in NEJM, materially de-risks Sana’s hypoimmune platform and could attract partnering interest. FDA feedback on SC451 further validates the approach. While the $40-45 m impairment is headline-negative, it is non-cash and reflects a pragmatic shift toward outsourced manufacturing, reducing future capex. Cash of $90 m plus ATM proceeds extends runway but still implies financing needs within 12-18 months, typical for clinical-stage biotech. Leadership loss of Dr. Schrepfer introduces execution risk around hypoimmune programs. Net impact: modestly positive for long-term science-driven investors.

TL;DR: Filing is mixed; liquidity stable, but impairment and key resignation add risk.

Non-cash write-down of up to $45 m will inflate GAAP loss and may pressure near-term sentiment. Outsourcing lowers fixed cost but indicates limited internal scale. Cash of $90 m covers roughly a year of operations based on prior burn rates; ATM usage evidences ongoing reliance on equity markets amid rising rates. Departure of the platform head could slow development and complicate talent retention. Clinical momentum is encouraging yet early-stage. I view overall impact as balanced, leaning neutral.

Sana Biotechnology (NASDAQ: SANA) ha presentato un modulo 8-K divulgando i principali sviluppi del secondo e terzo trimestre. L'azienda stima di aver detenuto 90,1 milioni di dollari in contanti, equivalenti di cassa e titoli negoziabili al 31 luglio 2025. Tra il 1° aprile e il 6 agosto 2025 ha raccolto 29,1 milioni di dollari di proventi netti attraverso la vendita di 7.441.376 azioni ordinarie nell'ambito del suo programma di vendita sul mercato.

Sana registrerà una perdita non monetaria di valore compresa tra 40 e 45 milioni di dollari a maggio 2025, legata alla sospensione della costruzione e ai subaffitti pianificati delle sue strutture di Bothell e Seattle. Dal punto di vista operativo, i dati a sei mesi di giugno 2025 dello studio UP421, promosso da un investigatore, hanno soddisfatto tutti gli endpoint primari e secondari, dimostrando la funzione delle cellule β produttrici di insulina senza immunosoppressione; i risultati sono stati successivamente pubblicati su NEJM. Il candidato pre-clinico SC451 ha fatto progressi dopo un incontro positivo con la FDA INTERACT. Al contrario, la Vicepresidente Senior e Responsabile della Piattaforma Hypoimmune, la dott.ssa Sonja Schrepfer, si è dimessa. Tutte le cifre finanziarie sono non revisionate e soggette a modifiche.

Sana Biotechnology (NASDAQ: SANA) presentó un formulario 8-K divulgando desarrollos clave del segundo y tercer trimestre. La compañía estima que tenía 90,1 millones de dólares en efectivo, equivalentes de efectivo y valores negociables al 31 de julio de 2025. Entre el 1 de abril y el 6 de agosto de 2025, recaudó 29,1 millones de dólares netos mediante la venta de 7.441.376 acciones comunes bajo su programa de colocación en el mercado.

Sana registrará una pérdida por deterioro no monetaria de 40 a 45 millones de dólares en mayo de 2025, vinculada a la suspensión de la construcción y los subarrendamientos planificados de sus instalaciones en Bothell y Seattle. Operativamente, los datos a seis meses de junio de 2025 del ensayo patrocinado por investigadores UP421 cumplieron con todos los objetivos primarios y secundarios, demostrando la función de células β productoras de insulina sin inmunosupresión; los resultados fueron publicados posteriormente en NEJM. El candidato preclínico SC451 avanzó tras una reunión favorable con la FDA INTERACT. Por otro lado, la Vicepresidenta Senior y Jefa de la Plataforma Hypoimmune, la Dra. Sonja Schrepfer renunció. Todas las cifras financieras son no auditadas y están sujetas a cambios.

Sana Biotechnology (NASDAQ: SANA)ëŠ� 2분기와 3분기 주요 ì§„í–‰ ìƒí™©ì� 공개하는 8-K 보고서를 제출했습니다. 회사ëŠ� 2025ë…� 7ì›� 31ì� 기준 현금, 현금ì„� ìžì‚° ë°� 시장ì„� ì¦ê¶Œìœ¼ë¡œ 9,010ë§� 달러ë¥� 보유í•� 것으ë¡� 추정합니ë‹�. 2025ë…� 4ì›� 1ì¼ë¶€í„� 8ì›� 6ì¼ê¹Œì§€ 시장 ë‚� 프로그램ì� 통해 7,441,376ì£¼ì˜ ë³´í†µì£¼ë¥¼ íŒë§¤í•˜ì—¬ 2,910ë§� 달러ì� 순수ìµì„ 조달했습니다.

SanaëŠ� 2025ë…� 5ì›”ì— ë³´í…” ë°� 시애틀 시설ì� 건설 중단 ë°� 계íšë� 서브리스와 관련하ì—� 4,000ë§Œ~4,500ë§� 달러ì� 비현ê¸� ì†ìƒì°¨ì†ì� 기ë¡í•� 예정입니ë‹�. ìš´ì˜ ì¸¡ë©´ì—서, 2025ë…� 6ì›”ì— ì¡°ì‚¬ìž� ì£¼ë„ UP421 ìž„ìƒì‹œí—˜ì� 6개월 ë°ì´í„°ëŠ” 모든 1ì°� ë°� 2ì°� í‰ê°€ë³€ìˆ˜ë¥¼ 충족했으ë©�, 면역억제 ì—†ì´ ì¸ìŠë¦� ìƒì‚° ë² íƒ€ì„¸í¬ ê¸°ëŠ¥ì� ìž…ì¦í–ˆìŠµë‹ˆë‹¤; ê²°ê³¼ëŠ� ì´í›„ NEJMì—� 게재ë˜ì—ˆìŠµë‹ˆë‹�. ì „ìž„ìƒ� 후보물질 SC451ì€ FDA INTERACT 회ì˜ì—서 ê¸ì •ì ì¸ í‰ê°€ë¥� 받아 ì§„ì „ì� 보였습니ë‹�. 반면, Hypoimmune 플랫í¼ì˜ ìˆ˜ì„ ë¶€ì‚¬ìž¥ ê²� ì±…ìž„ìžì¸ ì†ì•¼ 슈레í� ë°•ì‚¬ë‹˜ì´ ì‚¬ìž„í–ˆìŠµë‹ˆë‹¤. 모든 재무 수치ëŠ� ê°ì‚¬ë˜ì§€ 않았으며 ë³€ê²½ë  ìˆ� 있습니다.

Sana Biotechnology (NASDAQ : SANA) a déposé un formulaire 8-K révélant les principaux développements des deuxième et troisième trimestres. La société estime détenir 90,1 millions de dollars en liquidités, équivalents de liquidités et titres négociables au 31 juillet 2025. Entre le 1er avril et le 6 août 2025, elle a levé 29,1 millions de dollars de produits nets grâce à la vente de 7 441 376 actions ordinaires dans le cadre de son programme de placement en continu.

Sana enregistrera une dépréciation non monétaire de 40 à 45 millions de dollars en mai 2025, liée à la suspension de la construction et aux sous-locations prévues de ses installations de Bothell et Seattle. Sur le plan opérationnel, les données à six mois de juin 2025 de l'essai UP421, sponsorisé par un investigateur, ont atteint tous les critères principaux et secondaires, démontrant la fonction des cellules β productrices d'insuline sans immunosuppression ; les résultats ont ensuite été publiés dans le NEJM. Le candidat préclinique SC451 a progressé suite à une réunion favorable avec la FDA INTERACT. En revanche, la vice-présidente senior et responsable de la plateforme Hypoimmune, Dr Sonja Schrepfer, a démissionné. Toutes les données financières sont non auditées et susceptibles d’être modifiées.

Sana Biotechnology (NASDAQ: SANA) reichte ein 8-K ein, in dem wichtige Entwicklungen im zweiten und dritten Quartal offengelegt wurden. Das Unternehmen schätzt, dass es am 31. Juli 2025 über 90,1 Millionen US-Dollar an Bargeld, Zahlungsmitteln und marktfähigen Wertpapieren verfügte. Zwischen dem 1. April und dem 6. August 2025 erzielte es 29,1 Millionen US-Dollar Nettoproven durch den Verkauf von 7.441.376 Stammaktien im Rahmen seines At-the-Market-Programms.

Sana wird im Mai 2025 eine nicht zahlungswirksame Wertminderung in Höhe von 40 bis 45 Millionen US-Dollar verbuchen, die mit der Aussetzung des Ausbaus und den geplanten Untermietungen seiner Einrichtungen in Bothell und Seattle zusammenhängt. Operativ erfüllten die sechsmonatigen Daten der im Juni 2025 vom Prüfer initiierten UP421-Studie alle primären und sekundären Endpunkte und zeigten eine Insulin-produzierende β-Zellfunktion ohne Immunsuppression; die Ergebnisse wurden später im NEJM veröffentlicht. Der präklinische Kandidat SC451 machte Fortschritte nach einem positiven FDA-INTERACT-Treffen. Im Gegensatz dazu trat Dr. Sonja Schrepfer, Senior Vice President und Leiterin der Hypoimmune-Plattform, zurück. Alle finanziellen Zahlen sind unauditiert und können sich ändern.

false 0001770121 0001770121 2025-08-06 2025-08-06
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2025

 

 

SANA BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39941   83-1381173

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

188 East Blaine Street, Suite 400

Seattle, Washington 98102

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (206) 701-7914

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   SANA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 
 


Item 2.02

Results of Operations and Financial Condition.

The information set forth in Item 8.01 under the caption “Certain Preliminary Financial Information (Unaudited)” is incorporated into this Item 2.02 by reference.

 

Item 8.01

Other Events.

Certain Preliminary Financial Information (Unaudited)

Sana Biotechnology, Inc. (the “Company”) reports that it estimates its cash, cash equivalents, and marketable securities as of July 31, 2025 were approximately $90.1 million.

Additionally, as a result of changes in the Company’s business plans and intention to pursue potential subleases for the Company’s Bothell, Washington and Seattle, Washington facilities, as well as the Company’s decision to suspend further build-out of internal manufacturing capabilities in the near-term at the facility in Bothell due to increased availability of manufacturing capacity at third-party contract development and manufacturing organizations for cell and gene therapy products, as well as progress in understanding the Company’s near-term manufacturing needs, and other factors, the Company determined that a triggering event occurred and performed an impairment analysis in the second quarter of 2025. As of March 31, 2025, leasehold improvements, construction in progress, and operating lease right-of-use assets were $33.3 million, $40.4 million, and $54.8 million, respectively. Based upon preliminary estimates and information available to the Company as of the date of this Current Report on Form 8-K (this “Report”), the Company expects to recognize non-cash impairment losses of approximately $40.0 million to $45.0 million related to the Bothell and Seattle facilities in the month ended May 31, 2025.

These estimates of the Company’s cash, cash equivalents, and marketable securities as of July 31, 2025 and the non-cash impairment losses for the month ended May 31, 2025 are preliminary, have not been audited, are based on information available to the Company as of the filing of this Report, and are subject to change. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position as of July 31, 2025 and for the month ended May 31, 2025. The Company’s independent registered public accounting firm has not audited, reviewed, or performed any procedures with respect to this preliminary information and, accordingly, does not express an opinion or any other form of assurance about it.

Between April 1, 2025 and the date of this Report, the Company sold an aggregate of 7,441,376 shares of its common stock pursuant to its sales agreement dated May 8, 2025 with TD Securities (USA) LLC, as sales agent, in “at-the-market” offerings, for net proceeds of $29.1 million.

Clinical Updates

In June 2025, the Company announced positive six-month results from the UP421 investigator-sponsored trial demonstrating that all primary and secondary endpoints were met. Results of the study through six months after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase with a mixed meal tolerance test during testing at these timepoints, consistent with insulin secretion in response to a meal. 12-week PET-MRI scanning also demonstrated islet cells at the transplant site, a forearm muscle. The study identified no safety issues, and the hypoimmune platform technology (HIP)-modified islet cells evaded immune detection. The trial continues to evaluate safety, persistence, and function of the transplanted cells. On August 4, 2025, the New England Journal of Medicine published a journal article titled “Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression,” which discusses the 12-week results of the trial. In June 2025, the six-month results of the trial were presented at the 85th Annual American Diabetes Association (ADA) Scientific Sessions. The Company and its collaborators at Uppsala University Hospital expect to report additional data from the study, including longer-term follow-up, as the year progresses. In addition, the Company is continuing pre-clinical development of SC451, and a recent FDA INTERACT meeting increases the Company’s confidence in moving forward with its HIP-edited master cell bank for good manufacturing practices (GMP) manufacturing and its non-clinical testing plan.

Personnel Update

Sonja Schrepfer, MD, PhD, the Company’s Senior Vice President and Head of the Hypoimmune Platform, has resigned as an employee to pursue other opportunities.


Cautionary Note Regarding Forward-Looking Statements

This Report contains forward-looking statements, including statements about the Company’s preliminary estimates of cash, cash equivalents, and marketable securities as of July 31, 2025 and non-cash impairment losses for the month ended May 31, 2025, the Company’s intention to pursue potential subleases for the Bothell, Washington and Seattle, Washington facilities, the Company’s beliefs relating to its observations of data from the UP421 investigator-sponsored trial as well as expectations regarding the availability and timing of additional clinical data to be generated and reported by the Company, and the impact of the FDA INTERACT meeting and feedback and the ability to move forward with the Company’s HIP-edited master cell bank for GMP manufacturing and non-clinical testing plan for SC451. These forward-looking statements reflect the Company’s views regarding current expectations and projections about future events and conditions and are based on currently available information. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict, including risks related to preliminary financial results, such as the risks that the preliminary financial information reflects information available to the Company only at this time and may differ from actual results, risks and uncertainties associated with discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as a clinical stage company, including the potential for the Company’s product candidates to cause serious adverse events, the timing, progress and results of the Company’s clinical trials, the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results, regulatory risks, and the Risk Factors identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025; therefore, the Company’s actual results could differ materially from those expressed, implied or forecast in any such forward-looking statements. Expressions of future goals and expectations and similar expressions, including “may,” “will,” “should,” “could,” “aims,” “seeks,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “predicts,” “potential,” “targets,” and “continue,” reflecting something other than historical fact are intended to identify forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. However, readers should carefully review the reports and documents the Company files or furnishes from time to time with the SEC, particularly its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Sana Biotechnology, Inc.
Date: August 6, 2025     By:  

/s/ Bernard J. Cassidy

            Bernard J. Cassidy
            Executive Vice President and General Counsel

FAQ

How much cash does Sana Biotechnology (SANA) report as of 31 July 2025?

The company estimates approximately $90.1 million in cash, cash equivalents, and marketable securities.

What impairment charge will SANA record in Q2-2025?

Sana expects a non-cash impairment of $40�45 million related to its Bothell and Seattle facilities.

How many shares did Sana sell through its ATM program and for how much?

Between 1 Apr and the filing date, Sana sold 7,441,376 shares for $29.1 million in net proceeds.

What were the key results of the UP421 trial announced in June 2025?

The six-month data showed survival and insulin-producing function of transplanted beta cells with no safety issues or immunosuppression required.

Which senior executive resigned from Sana Biotechnology?

Dr. Sonja Schrepfer, Senior Vice President and Head of the Hypoimmune Platform, resigned to pursue other opportunities.
Sana Biotechnology, Inc.

NASDAQ:SANA

SANA Rankings

SANA Latest News

SANA Latest SEC Filings

SANA Stock Data

850.54M
226.39M
7.75%
78.03%
13.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SEATTLE